Loading company
$7.350.0%Sep 11 close
Figures through June 30, 2026, from the 10-Q filed August 11, 2026
Past performance
- 3M
- +1.2%
- 6M
- +83.1%
- 1Y
- +83.7%
- 5Y
- -49.6%
$7.350.0%Sep 11 close
Figures through June 30, 2026, from the 10-Q filed August 11, 2026
From the company’s own 8-K filing.
AtaiBeckley Inc. has no earnings call transcript available.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable, and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from AtaiBeckley Inc.’s Item 2.02 8-K filed May 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.